BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Consensus Rating of “Hold” by Analysts

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has been given an average rating of “Hold” by the four analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $11.00.

Several analysts recently issued reports on the company. Wall Street Zen downgraded BioXcel Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. HC Wainwright lowered their price objective on BioXcel Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Rodman & Renshaw started coverage on BioXcel Therapeutics in a research report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Monday, April 20th.

Institutional Trading of BioXcel Therapeutics

A number of large investors have recently modified their holdings of the company. Millennium Management LLC acquired a new position in BioXcel Therapeutics during the 3rd quarter valued at about $2,632,000. Jane Street Group LLC acquired a new stake in shares of BioXcel Therapeutics in the fourth quarter valued at approximately $204,000. Geode Capital Management LLC increased its stake in shares of BioXcel Therapeutics by 64.6% in the fourth quarter. Geode Capital Management LLC now owns 206,168 shares of the company’s stock valued at $330,000 after purchasing an additional 80,928 shares during the period. Man Group plc bought a new stake in shares of BioXcel Therapeutics during the fourth quarter valued at approximately $91,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of BioXcel Therapeutics during the first quarter valued at approximately $50,000. Institutional investors and hedge funds own 30.68% of the company’s stock.

BioXcel Therapeutics Stock Down 22.9%

Shares of NASDAQ:BTAI opened at $0.80 on Thursday. The company has a market cap of $24.77 million, a PE ratio of -0.14 and a beta of 0.27. BioXcel Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $8.08. The firm has a 50-day simple moving average of $1.19 and a 200 day simple moving average of $1.42.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its earnings results on Friday, May 15th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.01). The business had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.38 million. As a group, research analysts forecast that BioXcel Therapeutics will post -2.07 EPS for the current fiscal year.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.